Tune Therapeutics

Seattle, Washington, USA and Durham, North Carolina, USA

Tune Therapeutics develops TEMPO, an epigenomic platform that fine-tunes gene activity without altering DNA. It is developing therapies for chronic hepatitis B, rare single-gene disorders and other conditions.

Facts

HQ
Seattle, Washington, USA and Durham, North Carolina, USA
Sectors
Biotechnology, Therapeutics, Epigenomics
Stage
Series B
Members see funding amounts.
.

Is this your organization? Claim it

Blue Origin's New Glenn Rocket Achieves First Orbital Launch Amid Schedule Hiccups; Microsoft Creates New AI Division Led by Ex-Facebook Chief; Truveta Raises $320M for Genome Initiative

Jeff Bezos' Blue Origin faced multiple scheduling changes before successfully launching its heavy-lift New Glenn rocket to orbit for the first time. Additionally, Microsoft established a new AI division led by a former Facebook engineering chief, and Seattle's Truveta secured $320 million to start a large genome project.

See all 6 stories, episodes and videos about Tune Therapeutics.